You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retatrutide-Obesity
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
In the retatrutide TRIUMPH-1 and TRIUMPH-2 trials, what criteria were pre-defined for dose modification?
TRIUMPH-1 and TRIUMPH-2 included predefined criteria for dose modification based on gastrointestinal tolerability, inadequate nutrition or dehydration, and perceived excessive weight loss or body mass index ≤22 kg/m².
What were the criteria for dose modifications in TRIUMPH-1 and TRIUMPH-2?
In TRIUMPH-1 and TRIUMPH-2, treatment dose modification was permitted up to two times
- for intolerable gastrointestinal (GI) symptoms during the first 20 weeks of the study if mitigation strategies to alleviate GI symptoms were not effective1,2
- at any time during the study, to address inadequate nutrition or dehydration if mitigation strategies to alleviate GI symptoms and improve nutrition and/or hydration were not effective, and1,2
- at any time during the study, for body mass index ≤22 kg/m², or excessive weight loss as perceived by either the participant or the investigator.1,2
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Jastreboff AM, Kaplan LM, Davies MJ, et al; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. Published online September 29, 2026. https://doi.org/10.1056/NEJMoa2604169
- Bellido V, le Roux CW, Ekinci E, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. Published online September 29, 2026. https://doi.org/10.1016/S0140-6736(26)01861-1
Date of Last Review: September 30, 2026